🇪🇺 Signifor (pasireotide) in European Union

EMA authorised Signifor (pasireotide) on 24 April 2012

Marketing authorisation

EMA — authorised 24 April 2012

  • Application: EMEA/H/C/002052
  • Marketing authorisation holder: Recordati Rare Diseases
  • Local brand name: Signifor
  • Indication: Signifor is indicated for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed. Signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
  • Status: approved

Read official source →

Signifor (pasireotide) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Endocrinology approved in European Union

Frequently asked questions

Is Signifor (pasireotide) approved in European Union?

Yes. EMA authorised it on 24 April 2012.

Who is the marketing authorisation holder for Signifor (pasireotide) in European Union?

Recordati Rare Diseases holds the EU marketing authorisation.